29Jul
National Retailer Pulls CBD Products From Shelves in Response to FDA Warning to Product Manufacturer
On Monday, July 22, the U.S. Food and Drug Administration (FDA) took a rare and significant step in issuing a warning letter to Curaleaf Holdings, Inc. (Curaleaf), one of the country’s larger producers of CBD-based products, regarding Curaleaf’s...
By:
Manatt, Phelps & Phillips, LLP
Related
In Appeal of Watts Constructors, LLC, the Armed Services Board of Contract Appeals (the “Board”) h...
Read More >
As July 15th draws closer, EEOC and NORC are ramping up for opening of the EEO-1 Component 2 Pay Dat...
Read More >
The United States Environmental Protection Agency (“EPA”) Office of Inspector General (“OIG”) is...
Read More >
About this time last year, research from George Washington University and University of Utah found a...
Read More >
Last month, the United States Court of Appeals for the Ninth Circuit certified two questions of stat...
Read More >
On January 31, 2020, the U.S. Citizenship and Immigration Services (USCIS) published a new edition o...
Read More >